Navigation Links
Organovo Announces Collaboration with National Institutes of Health
Date:1/14/2014

SAN DIEGO and BETHESDA, Md., Jan. 14, 2014 /PRNewswire/ -- Organovo announced today that they are joining together with two institutes from the National Institutes of Health (NIH) to help scientists develop more reliable tools for bringing safer, more effective treatments to patients on a faster timeline. Organovo is collaborating with the National Center for Advancing Translational Sciences (NCATS) and the National Eye Institute (NEI) to develop better and more clinically predictive tissue models using Organovo's NovoGen MMX Bioprinter®. Organovo will collaborate with NCATS and NEI in using the NovoGen Bioprinting platform to create three-dimensional, architecturally correct, functional living tissues.

"Researchers who develop new therapies for patients are too often hampered by animal models and traditional cell culture models that are poor predictors of drug efficacy and toxicity in human beings," says Keith Murphy, Organovo's Chief Executive Officer. "Our 3D printer creates living human tissues that more closely reproduce in vivo human tissues.  In collaboration with NIH, which has worked to highlight and address the critical need for better models that can lead to better drugs, we hope to create tissue models that give researchers a much more accurate view of how drugs will behave in human beings before those drugs ever enter clinical trials."

"Developing collaborations like this are central to NCATS' mission," said NCATS Director Christopher P. Austin, M.D. "We look forward to working with Organovo and our colleagues at NEI to develop a printable eye tissue. We also plan to develop additional tissue models that complement and leverage our current Tissue Chip and compound screening programs."

"This technology could provide us with a renewable and easy-to-manipulate source of functional eye tissue," said NEI Director Paul A. Sieving, M.D., Ph.D. "Printable eye tissue could be used to identify disease pathways and to screen for and discover new therapeutic drugs."

For more information about NCATS and NEI, visit www.ncats.nih.gov and www.nei.nih.gov.

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance for the Company's products, and the risks related to the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our report on Form 10-Q filed November 8, 2013, the prospectus supplement filed with the SEC on August 2, 2013 and the transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
2. Organovo Reports Q1 Fiscal 2014 Results, Provides Business Update
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. Organovo Announces the Nomination of Richard A. Heyman to Board of Directors
5. Organovo Rings Opening Bell On New York Stock Exchange
6. OTC Markets Group Congratulates Organovo Holdings on Move to NYSE MKT
7. Organovo To List Common Stock On New York Stock Exchange MKT
8. Organovo Appoints Tamar D. Howson to Board of Directors
9. Organovo to Present at the 12th Annual Needham Healthcare Conference
10. Organovo Partners With ZenBio to Create 3D Tissue Models
11. Organovo Holdings, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Biocom, the association representing the Southern California ... San Diego companies to Washington D.C. ... Fly-In. Biocom Fly-In participants had the opportunity to meet with ... for Medicare and Medicaid Services (CMS), the National Institutes of ... Susan Davis and Scott Peters to discuss ...
(Date:2/12/2016)... Feb. 12, 2016  BD (Becton, Dickinson and Company) ... company, today announced the launch of the BD CLiC™ ... Technology (AGBT) Meeting. --> ... research by providing cost effective NGS library preparation with ... high-throughput, fully integrated, next generation sequencing (NGS) library prep ...
(Date:2/12/2016)... SAN FRANCISCO , February 12, 2016 /PRNewswire/ ... Precision Medicine Efforts by Enabling Scientific Understanding of ... Disorders and Rare Diseases --> ... for genomic diagnostics in South Asia and a leading ... it would contribute $10 million to the GenomeAsia ...
(Date:2/11/2016)... Inc. (NASDAQ: NBIX ) today announced its financial results for ... --> --> For the fourth quarter of ... $0.34 loss per share, compared to a net loss of $19.4 ... 2014. For the year ended December 31, 2015, the Company reported ... as compared to a net loss of $60.5 million, or $0.81 ...
Breaking Biology Technology:
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
(Date:1/20/2016)... -- A market that just keeps on growing. Molecular ... in genomics knowledge. Learn all about it in this ... dynamic trends are pushing market growth and company valuations. ... - pathogen evolution - next generation sequencing - emergence ... of the role of genetic material in Disease and ...
Breaking Biology News(10 mins):